Forum Topics AVR AVR Media coverage

Pinned straw:

Last edited 2 months ago

Legacy Media

6764c2d0e0e06422f9d9e9ac1a5e2df8fcf87c.jpeg

It’s a shame no one interesting actually tweets anymore. Otherwise people would see this instead of wading through AI generated engagement and the trivial grievances of the world’s richest man.

f7e5919fbe2a72345f48e7cd09463ac0b3d8b2.png

It’s also a shame no one watches free to air TV anymore. Otherwise they would be able to catch a pretty slick infomercial hosted by Meg Ryan on CNBC in the United States tomorrow our time.

And it’s a shame that I’m part of a group which is getting smaller in that I remember Meg Ryan. It’s also a shame that emails are almost never exciting these days.

I am certainly no expert, so I can’t fault them. I don’t know where the eyeballs are going these days. More important than all this however is why is Anteris doing paid advertising in the first place? They have no marketable product at this stage, and recruiting for the FDA trial is some time away yet. True, there are a few ads about for jobs, some of them key positions, but a television campaign for a few jobs seems like overkill. However, the real product at the moment — I think — is the shares themselves.

The fiscally conservative value investor in me (there is still a bit of him there) does wonder how much we actually paid for this.

Out of further curiosity — and because I hadn’t heard the name for a while — I Googled this.

ef7953da6872a271a4c63f44555c6923ac126e.jpeg

I’m sure that it’s just a coincidence that this figure is about the same as the $88 million USD raised in the IPO.

I’m confident they know what they’re doing.

Scoonie
Added 2 months ago

Had had a look at the Meg Ryan "Empowered” website and the Anteris "news article".

I agree PabloEskyBruh Anteris being without a marketable product and being years off any FDA approval, why have they paid to have cutesy Meg Ryan promote them?  Can only think that it is a reflection of the hyper competitive nature of the US, where to have a chance of winning you need to pull out every stop.

Reminds me somewhat of the US tipping culture, where the restaurant wait staff are invariably gushingly super nice in the quest for tips.  At the places I visited the waitresses would practically push their ample cleavages into your face as they took your drinks order. (For the record, in my whole time in the USA I never once complained to either the staff member concerned or management about this kind of behaviour).

Anyway, at least with the Aussie waitress both the smile and cleavage are usually genuine.

11
PabloEskyBruh
Added 2 months ago

Where some of the other money is going:

https://theorg.com/org/anteris-technologies/jobs/medical-sewer-contract-38d72c60

Whilst Anteris’ DurAVR requires less stitches than either Sapien or Evolut it still needs some. The single piece valve starts as a treated rectangular piece of bovine tissue. Anteris has the patent for this.

These sewing positions in Minnesota are to supplement — not replace — those at Malaga, Western Australia. The MN facility is already up and running but this is about scaling up. Production is very slow as you would expect for such a precise and vital device. They will need to produce hundreds for the next couple of years, and thousands — even tens of thousands — thereafter if successful.

9

PabloEskyBruh
Added 2 months ago

This is a quote from CEO Wayne Paterson in his interview with Alan Kohler in April 2022:

d2d96b17ed1643c41e1e39e08b0720a17158ca.jpeg

8
thetjs
Added 2 months ago

America’s approach to healthcare blows me away.

Who is this ads targeted at? The patient? The doctor?

Is there a large pool of cardiac surgeon, Meg Ryan fans who’s interest would be spiked to look further into this product?

6

PabloEskyBruh
Added 2 months ago

It is interesting isn’t it @thetjs? I think it’s broader than the patient or doctor at the moment. It has to be when there is no FDA approval yet. There are special use/exemption cases in Canada for valve-in-valve but this is not the thrust of the advertisement at all. And doctors just can’t choose it yet. I’d also hazard a guess that nearly all the interventional cardiologists— certainly all the centres anyway — to be used in the FDA pivotal trial are already know of Anteris.

Which largely leaves the equity space. Which in the US is just bigger. In addition to the mum and dad investors who are just waiting to watch the 5pm news there are others it reaches: Capital allocators at big institutional funds who are looking to add something to growth portfolios; mainstream financial media looking for an exciting med-tech stock to add to a weekly column; the corporate heirarchy of Anteris competitors themselves; and the subordinates, underlings, friends and family members of all those people who could bring it to their attention.

I think it is also about just insisting at a seat at the big-boy table and demanding to be taken seriously. Every extra step along this path is a cost multiplier to incumbents like Edwards or Medtronic or companies like Johnson & Johnson looking for a flagship TAVR acquisition. And every successful step makes an acquisition that much less necessary from Anteris’ perspective.

Looking at the website there are quite a few other commercials Meg does and it has a curated feel. I think this is just one of the things she does now, so thankfully not some exclusive ad hoc one-off thing Anteris lined up at some outlandish cost.

9

PabloEskyBruh
Added 2 months ago

Looking at it more I’d say that if Anteris does have a need for this engagement then this is the type of platform to use:

https://www.empoweredprogram.com/about-us/

I like their focus on narrative. I think this is now Anteris’ strength. Especially in the US where it is new and has no baggage. They have a good story to sell. Outside of the dedicated active investing community that matters a lot more.

8